Turn Therapeutics Inc. has made significant strides in its clinical trials for GX-03, a treatment aimed at inflammatory skin diseases. The company announced positive results from its Stage 1/Phase 2a trial, which showed that 59.3% of patients achieved clear or almost clear skin after four weeks of treatment. This progress is crucial for Turn Therapeutics as it continues to develop targeted therapies for conditions like atopic dermatitis and hidradenitis suppurativa.
In its recent filing, Turn Therapeutics provided updates on its financial and operational results for the quarter ending September 30, 2026. The company is listed under the SIC code 2834, which covers pharmaceutical preparations, and trades on the Nasdaq under the ticker TTRX. The filing was made on November 9, 2026, and included a press release detailing the latest trial outcomes.
The filing highlights that the Stage 1 trial of GX-03 yielded promising results, with a notable difference in skin improvement compared to the control group. Specifically, 40.7% of patients treated with GX-03 achieved a complete resolution of eczema, as measured by the Eczema Area and Severity Index (EASI), at the eight-week mark. This is a significant improvement over the 17.4% observed in the control group. Bradley Burnam, the CEO of Turn Therapeutics, emphasized the importance of these results in refining their ongoing Phase 2b trial.
In addition to these developments, Turn Therapeutics is set to accelerate its Phase 2a trial for hidradenitis suppurativa, a chronic skin condition affecting many adults. The company expects to begin patient enrollment in the first quarter of 2027, ahead of its previous timeline. This trial will evaluate the efficacy of GX-03 in treating active inflammatory lesions associated with hidradenitis suppurativa.
The updates from Turn Therapeutics are likely to impact patients suffering from chronic skin conditions, as well as the broader pharmaceutical industry, which is increasingly focusing on innovative treatments for such ailments. The company has also appointed former CDC Director Robert R. Redfield, M.D., as its Chief Scientific Officer, further strengthening its leadership team.
Looking ahead, Turn Therapeutics is optimistic about its cash flow, expecting to fund operations into the third quarter of 2027. The company has additional capital available from existing facilities, which will support its ongoing trials and research initiatives.
The filing does not specify any immediate next steps beyond the ongoing trials and expected enrollment for the hidradenitis suppurativa study.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










